FibroGen (FGEN) Competitors $5.69 +0.44 (+8.38%) Closing price 07/3/2025 03:52 PM EasternExtended Trading$5.61 -0.08 (-1.41%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FGEN vs. FBRX, CHRS, CLLS, CRBP, CLYM, ZNTL, JSPR, EXOZ, TCRX, and ELUTShould you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Forte Biosciences (FBRX), Coherus Oncology (CHRS), Cellectis (CLLS), Corbus Pharmaceuticals (CRBP), Climb Bio (CLYM), Zentalis Pharmaceuticals (ZNTL), Jasper Therapeutics (JSPR), eXoZymes (EXOZ), TScan Therapeutics (TCRX), and Elutia (ELUT). These companies are all part of the "pharmaceutical products" industry. FibroGen vs. Its Competitors Forte Biosciences Coherus Oncology Cellectis Corbus Pharmaceuticals Climb Bio Zentalis Pharmaceuticals Jasper Therapeutics eXoZymes TScan Therapeutics Elutia Forte Biosciences (NASDAQ:FBRX) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation. Does the media refer more to FBRX or FGEN? In the previous week, FibroGen had 1 more articles in the media than Forte Biosciences. MarketBeat recorded 2 mentions for FibroGen and 1 mentions for Forte Biosciences. FibroGen's average media sentiment score of 1.94 beat Forte Biosciences' score of 0.00 indicating that FibroGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral FibroGen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders and institutionals believe in FBRX or FGEN? 77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 72.7% of FibroGen shares are held by institutional investors. 5.9% of Forte Biosciences shares are held by insiders. Comparatively, 3.1% of FibroGen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is FBRX or FGEN more profitable? Forte Biosciences has a net margin of 0.00% compared to FibroGen's net margin of -9.73%. FibroGen's return on equity of 0.00% beat Forte Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Forte BiosciencesN/A -149.15% -114.25% FibroGen -9.73%N/A -24.77% Do analysts recommend FBRX or FGEN? Forte Biosciences presently has a consensus target price of $61.00, indicating a potential upside of 341.71%. FibroGen has a consensus target price of $250.00, indicating a potential upside of 4,293.67%. Given FibroGen's higher possible upside, analysts plainly believe FibroGen is more favorable than Forte Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has stronger valuation & earnings, FBRX or FGEN? Forte Biosciences has higher earnings, but lower revenue than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioForte BiosciencesN/AN/A-$35.48M-$16.29-0.85FibroGen$29.62M0.78-$47.58M-$2.50-2.28 Which has more risk and volatility, FBRX or FGEN? Forte Biosciences has a beta of 2.97, indicating that its share price is 197% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. SummaryForte Biosciences beats FibroGen on 8 of the 15 factors compared between the two stocks. Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FGEN vs. The Competition Export to ExcelMetricFibroGenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.99M$2.42B$5.50B$9.02BDividend YieldN/A1.77%5.38%4.10%P/E Ratio-2.289.1027.6020.30Price / Sales0.78490.15369.54104.24Price / CashN/A157.0736.6357.47Price / Book-0.114.638.055.68Net Income-$47.58M$31.34M$3.18B$249.13M7 Day Performance9.00%3.25%2.82%3.30%1 Month Performance-25.40%6.80%3.69%5.20%1 Year Performance-67.06%1.89%35.41%21.37% FibroGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FGENFibroGen4.7174 of 5 stars$5.69+8.4%$250.00+4,293.7%-67.1%$22.99M$29.62M-2.28570Positive NewsInsider TradeGap UpFBRXForte Biosciences3.1249 of 5 stars$12.93+5.6%$61.00+371.8%+67,782.4%$85.08MN/A-0.795CHRSCoherus Oncology3.7652 of 5 stars$0.73-1.6%$4.68+540.4%-42.4%$84.78M$266.96M-0.65330News CoverageCLLSCellectis3.0778 of 5 stars$1.53+5.2%$4.00+162.3%-22.7%$84.77M$47.63M-1.77290News CoverageGap DownCRBPCorbus Pharmaceuticals3.9048 of 5 stars$6.90-6.8%$50.88+637.3%-84.7%$84.44MN/A-1.6440CLYMClimb Bio2.6836 of 5 stars$1.24+5.1%$9.00+625.8%N/A$83.80MN/A-0.529ZNTLZentalis Pharmaceuticals1.5997 of 5 stars$1.16-1.7%$8.37+621.3%-64.1%$83.46M$67.43M-0.37160JSPRJasper Therapeutics1.9132 of 5 stars$5.55+1.1%$59.25+967.6%-68.3%$83.36MN/A-1.0620Gap UpEXOZeXoZymesN/A$9.88-4.9%N/AN/A$82.70M$70K0.0029News CoverageGap UpHigh Trading VolumeTCRXTScan Therapeutics2.0114 of 5 stars$1.45+3.6%$7.80+437.9%-74.2%$82.06M$2.82M-1.33100Positive NewsELUTElutia3.9183 of 5 stars$1.98-5.7%$8.00+304.0%-51.8%$81.41M$23.71M-1.03180Gap Down Related Companies and Tools Related Companies Forte Biosciences Competitors Coherus Oncology Competitors Cellectis Competitors Corbus Pharmaceuticals Competitors Climb Bio Competitors Zentalis Pharmaceuticals Competitors Jasper Therapeutics Competitors eXoZymes Competitors TScan Therapeutics Competitors Elutia Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FGEN) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
